Synthetic lethal interaction between ARID1A mutation and BET bromodomain inhibition in ovarian clear cell carcinoma

被引：2
|
作者：
Berns, Katrien
Caumanns, Joseph J.
Hijmans, E. Marielle
Gennissen, Annemiek
Evers, Bastiaan
Wisman, Bea A.
Meersema, Gert Jan
Lieftink, Cor
Beijersbergen, Roderick L.
Itamochi, Hiroaki
van der Zee, Ate G.
de Jong, Steven
Bernards, Rene
机构：
来源：
CANCER RESEARCH | 2017年 / 77卷
关键词：
D O I：
10.1158/1538-7445.AM2017-3380
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3380
引用
收藏
页数：2
相关论文
共 50 条
  • [21] ARID1A: A new synthetic lethality partner to PARP inhibitors in the treatment of ovarian clear cell cancer
    Yakovlev, V. A.
    Sullivan, S. A.
    Rubinsak, L. A.
    Fields, E. C.
    Temkin, S. M.
    GYNECOLOGIC ONCOLOGY, 2019, 154 : 78 - 78
  • [22] Evidence Supporting Endometriosis as a Precursor of Ovarian Clear Cell and Endometrioid Carcinoma Based on Expression of ARID1A
    Ayhan, A.
    Mao, T-L
    Wu, C-H
    Ogawa, H.
    Futagami, M.
    Mizukami, H.
    Yokoyama, Y.
    Kurman, R. J.
    Shih, I-M
    LABORATORY INVESTIGATION, 2012, 92 : 259A - 259A
  • [23] Identification of novel biomarkers of response to ATR inhibitors in ARID1A mutant ovarian clear cell carcinoma
    Stewart, J. R.
    Baxter, J.
    Zatreanu, D.
    Brough, R.
    Song, F.
    Konde, A.
    Krastev, D.
    Alexander, J.
    Natrajan, R.
    Pettitt, S.
    Banerjee, S.
    Lord, C.
    ANNALS OF ONCOLOGY, 2022, 33 : S383 - S384
  • [24] Ovarian clear cell carcinoma with an immature teratoma component showing ARID1A deficiency and an identical PIK3CA mutation
    Kihara, Atsushi
    Iizuka, Toshihiko
    Endo, Shinichi
    Horie, Koji
    Kanda, Hiroaki
    Niki, Toshiro
    JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH, 2021, 47 (09) : 3401 - 3407
  • [25] Evidence Supporting Endometriosis as a Precursor of Ovarian Clear Cell and Endometrioid Carcinoma Based on Expression of ARID1A
    Ayhan, A.
    Mao, T-L
    Wu, C-H
    Ogawa, H.
    Futagami, M.
    Mizukami, H.
    Yokoyama, Y.
    Kurman, R. J.
    Shih, I-M
    MODERN PATHOLOGY, 2012, 25 : 259A - 259A
  • [26] Genome-wide DNA methylation in relation to ARID1A deficiency in ovarian clear cell carcinoma
    Li, Shang
    Meersma, Gert Jan
    Kupryjanczyk, Jolanta
    de Jong, Steven
    Wisman, G. Bea A.
    JOURNAL OF TRANSLATIONAL MEDICINE, 2024, 22 (01)
  • [27] HDAC6 AS A THERAPEUTIC TARGET FOR OVARIAN CLEAR CELL CARCINOMA, IN ASSOCIATION WITH ARID1A LOSS
    Yano, M.
    Yasuda, M.
    Miyazawa, M.
    Miwa, M.
    Hasegawa, K.
    Narahara, H.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2018, 28 : 874 - 874
  • [28] SENSITIVITY TO CONVENTIONAL CHEMOTHERAPEUTIC DRUGS ACCORDING TO ARID1A DEFICIENCY OF OVARIAN CLEAR CELL CARCINOMA AND ENDOMETRIOID CARCINOMA CELLS
    Kuroda, T.
    Ogiwara, H.
    Takahashi, K.
    Sasaki, M.
    Yoshida, H.
    Kato, T.
    Okamoto, A.
    Kohno, T.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2018, 28 : 180 - 180
  • [29] Loss of ARID1A is a frequent event in clear cell and endometrioid ovarian cancers
    Lowery, W.
    Schildkraut, J.
    Akushevich, L.
    Bentley, R.
    Huntsman, D.
    Marks, J.
    Berchuck, A.
    GYNECOLOGIC ONCOLOGY, 2011, 121 (01) : S21 - S21
  • [30] ARID1A expression in ovarian clear cell carcinoma with an adenofibromatous component (vol 67, pg 866, 2014)
    Nishikimi, K.
    Kiyokawa, T.
    Tate, S.
    Iwamoto, M.
    Shozu, M.
    HISTOPATHOLOGY, 2016, 68 (04) : 621 - 621
12345